loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Dr. Reddy’s Lab has announced the first-to-market launch of Bosutinib Tablets in US

ICICIdirect Research 15 Jun 2026 DISCLAIMER

News: Dr. Reddy’s Lab has announced the first-to-market launch of Bosutinib Tablets in US. Dr. Reddy’s has collaborated with MSN Laboratories on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States while MSN is responsible for the development and manufacturing of the product. The medication is first-to-file product and is eligible for 180-days of generic drug exclusivity for this strength, in the US. As per IQVIA, the branded drug of the medication Bosulif has US sales of ~US$ 253.8 million for MAT April 26.

View: DRL plans to launch 27 new products in the US this year and was expecting Bosutinib among them to be strong opportunity. The launch timing is as per management guidance. We believe the product although would be less material for console topline, however given the niche nature with exclusivity it may contribute materially on bottom line.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere